After peaking in January, antiviral prescriptions dropped off in February. Though prescription fills remain at an elevated level as the flu continues to ravage the country, data from the GoodRx Index reveals that the worst of the flu season is over, resembling data from the Center for Disease Control and Prevention.
The GoodRx Index also showed other drug trends in February:
- The number of prescription fills are down by 16%, a typical seasonal variation.
- Prices for generic medications continued to increase.
- Average cash prices for a 30-day supply of Estradiol, a menopause drug, increased by 11%.
What do all of these numbers mean?
Prices in the GoodRx Index represent the list price at the pharmacy, also known as the ‘usual and customary’ price. While a majority of people pay for their prescriptions with insurance and are shielded from paying this ‘list price,’ more Americans every day are forced to pay out-of-pocket because of high deductibles, supply limits, or formulary exclusions. Additionally, an upward trend in list price indicates higher prices for both consumers and insurers, even if some insured people won’t be on the hook for the full price.
The Index is based on a nationally representative sample of prescription claims across the U.S.
In January, the GoodRx Index revealed that national prescription fills for Tamiflu (oseltamivir) were up by more than 5 times since last year. Some states in the south and midwest were hit especially hard, seeing as much as 14 times more prescription fills for Tamiflu compared to last year.
This upward trend has slackened in recent weeks, as 25% fewer prescriptions were filled for antiviral medications in February compared to January. Additionally, fills for benzonatate, used for cough, are down by almost 40%, and fills for azithromycin, used to treat viral cold and flu infections, are down by 17%. This pattern resembles data from the Centers for Disease Control and Prevention indicating a decline in flu-related hospitalizations and outpatient visits since late January.
Generics remain expensive
There’s been a lot of talk concerning generic pricing recently, and rightfully so. Generic drugs comprise 90% of the prescriptions Americans take, with millions of Americans depending on generics for affordable treatment, but prices have been steadily increasing. Over the past couple of months, cash prices for generic medications have increased by 7.5%, and that trend remained through February.
February’s big movers
Drug prices constantly fluctuate, changing incrementally month over month. One noteworthy price change in February occurred with Estradiol, a popular generic hormone used to treat menopause symptoms and prevent osteoporosis. Prices climbed by over 11% since January, rising from $78.93 to $88.44. This price increase is nothing new – back in 2013, the average cash price for a 30-day supply of Estradiol was a mere $26.
The most popular drugs in February 2018
Every month, GoodRx tracks the most popular drugs prescribed in the U.S., comparing total prescriptions written and filled for all forms of the medications. This analysis is based on a representative sample of prescriptions filled at U.S. pharmacies across the 50 states. The result is a top 10 list of the most prescribed drugs in the United States.
Some other drug news from February
- Last year Walgreens purchased over 1,900 Rite Aid Stores, and in February, these stores started to switch over to the Walgreens family. Learn more about how this may affect you here.
- GoodRx data revealed when the most romantic time of year is. Read more here. Hint – it’s not Valentines Day
- A treatment was approved in Japan that can beat the flu virus in just one day. It’s still a couple years out from being available in the U.S., but you can read about it here.
- Endo Pharmaceuticals discontinued Sumavel for migraines. You can read about options to replace Sumavel here.
- People with a high deductible shared their stories about using GoodRx. Read those here.